UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Arena Pharmaceuticals
In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Arena Pharmaceuticals (NASDAQ: ARNA), but lowered its price target from $20.00 to $14.00.
Jefferies noted, “ARNA reiterated its plans for Belviq (1Q13 U.S. launch) and outlined a new South Korean partnership with Ildong. We remain confident in the long-term potential for Belviq based on combination use with phentermine, but we are lowering our PT from $20 to $14, as we moderate our launch expectations for Belviq monotherapy following disappointing sales for competitor Qsymia.”
Arena Pharmaceuticals closed on Tuesday at $7.60.
Latest Ratings for ARNA
|Nov 2013||Wallachbeth||Initiates Coverage on||Buy|
|Oct 2013||Cowen & Company||Initiates Coverage on||Market Perform|
|Oct 2013||Piper Jaffray||Maintains||Overweight|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.